Early Stage

Accounting software for real people.

Accounting software for real people.


Raised this Round: Raised: $3,056

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Preferred

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share


Pre-Money Valuation


Year Founded



Business Services, Software, & Applications

Tech Sector


Wexford, Pennsylvania

Symbiotries is accounting software for real people. With their technology, you don’t need an accounting background to ensure you’re maximizing your dollars. The ywant to “empower small businesses to take control of their financial futures,” and their plan is to develop a cloud-based and desktop version of their accounting software package for both Macs and PCs. Right now, Symbiotries is in the development phase. In November 2017, they constructed the wireframe and started building the software, and they anticipate a November 2019 release.
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Symbiotries on StartEngine
Platform: StartEngine
Security Type: Equity - Preferred
Valuation: $4,397,500
Price per Share: $1.00

Follow company

Follow Symbiotries on StartEngine

Buy Symbiotries's Deal Report

Warning: according to the close date for this deal, Symbiotries may no longer be accepting investments.

Symbiotries Deal Report

Get KingsCrowd’s comprehensive report on Symbiotries including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Symbiotries is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Symbiotries deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge